429. Antibody Delivery by Genetically Engineered Human Hematopoietic Stem Cells to Fight HIV

Genetically Engineered Mesenchymal Stem Cells Stably Expressing Green Fluorescent Protein

Objective(s) Mesenchymal stem cells (MSCs) are nonhematopoietic stromal cells that are capable of differentiating into and contribute to the regeneration of mesenchymal tissues. Human mesenchymal stem cells (hMSCs) are ideal targets in cell transplantation and tissue engineering. Enhanced green fluorescent protein (EGFP) has been an important reporter gene for gene therapy. The aim of this stu...

Targeting TRAIL Receptors with Genetically- Engineered CD34+ Hematopoietic Stem Cells

genetically engineered mesenchymal stem cells stably expressing green fluorescent protein

objective(s) mesenchymal stem cells (mscs) are nonhematopoietic stromal cells that are capable of differentiating into and contribute to the regeneration of mesenchymal tissues. human mesenchymal stem cells (hmscs) are ideal targets in cell transplantation and tissue engineering. enhanced green fluorescent protein (egfp) has been an important reporter gene for gene therapy. the aim of this stud...

In Vivo Suppression of HIV by Antigen Specific T Cells Derived from Engineered Hematopoietic Stem Cells

The HIV-specific cytotoxic T lymphocyte (CTL) response is a critical component in controlling viral replication in vivo, but ultimately fails in its ability to eradicate the virus. Our intent in these studies is to develop ways to enhance and restore the HIV-specific CTL response to allow long-term viral suppression or viral clearance. In our approach, we sought to genetically manipulate human ...

Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.

The goal of cancer immunotherapy is the generation of an effective, stable, and self-renewing antitumor T-cell population. One such approach involves the use of high-affinity cancer-specific T-cell receptors in gene-therapy protocols. Here, we present the generation of functional tumor-specific human T cells in vivo from genetically modified human hematopoietic stem cells (hHSC) using a human/m...